Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Liver cancer, adult primary
Stage/Subtype:  stage D adult primary liver cancer (BCLC)
Trial Type:  Treatment
Results 1-25 of 44 for your search:
Start Over
Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection
Status: Active
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-213, NCI-2013-01103, NCT01849588
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-459, NCI-2015-01952, NCT02576509
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-240, NCI-2016-01269, 163456, 2015-004567-36, NCT02702401
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA223-001, NCI-2014-00201, NCT01714739
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA224-020, NCI-2014-00315, 2014-002605-38, NCT01968109
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Ipilimumab and Hypofractionated Stereotactic Body Radiation Therapy in Treating Patients with Advanced Solid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0882, NCI-2015-00042, NCT02239900
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBIHCC-103, NCI-2014-02447, BBI608-503-103HCC, NCT02279719
Trial of TRC105 and Sorafenib in Patients With HCC
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 105HCC101, NCI-2016-00131, NCT02560779
Enzalutamide with or without Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-279, NCI-2016-00062, NCT02642913
Sapanisertib or Sorafenib Tosylate in Treating Patients with Advanced or Metastatic Liver Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BTCRC GI13-002, NCI-2017-00470, NCT02575339
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CC-122-HCC-002, NCI-2017-00727, 2016-000112-15, NCT02859324
Hepatic Artery Embolization with Bumetanide in Treating Patients with Liver Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17-141, NCI-2017-00746, NCT03107416
A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: D4190C00022, NCI-2016-00207, NCT02519348
Partial Liver Transplant before Bone Marrow Transplant in Treating Patients with Liver Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 16 to 65
Trial IDs: j15171, NCI-2016-00821, IRB00080373, CRMS-62535, NCT02702960
Sphingosine Kinase-2 Inhibitor ABC294640 in Treating Patients with Advanced Liver Cancer Who Have Progressed on Sorafenib Tosylate
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 102418, NCI-2016-01585, NCT02939807
Sorafenib Tosylate and Hydroxychloroquine Sulfate in Treating Patients with Advanced or Metastatic Liver Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CTMS 16-0076, NCI-2017-00157, HSC20160515HU, NCT03037437
Transarterial Chemoembolization and Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-1671, NCI-2017-00672, NCT02513199
Ph 1 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: POLARIS2013-001, NCI-2017-00851, NCT02102022
Navitoclax and Sorafenib Tosylate in Treating Patients with Relapsed or Refractory Solid Tumors
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9608, NCI-2014-01043, MC1315, NCT02143401
Sonidegib in Treating Patients with Advanced or Metastatic Liver Cancer That Cannot Be Removed by Surgery or Child-Pugh A/B7 Cirrhosis
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLDE225XUS12T, NCI-2014-01762, HRPP #131053, 131053, NCT02151864
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SM04755-ONC-01, NCI-2014-02297, NCT02191761
Trametinib and Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17932, NCI-2014-02614, 14.10.0021, MCC 17932, NCT02292173
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B0601002, NCI-2015-00761, 2014-004107-75, NCT02315066
Study of E7046 in Subjects With Selected Advanced Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E7046-G000-101, NCI-2015-01544, NCT02540291
Start Over